Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine hydrochloride, the active ingredient in Orabloc, is a local anesthetic (amide type) presented as a solution for injection for local intraoral injection use. It provides reversible nerve block for dental procedures in patients requiring local anesthesia.

GNH USA supplies Orabloc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and timely delivery across multiple markets, ensuring product integrity and compliance with EU regulations through.

Orabloc, containing articaine, is employed for local anesthesia in dental procedures, acting on oral nerves to block sensation.

Dental extractions: provides profound anesthesia for removal of teeth, reducing pain and discomfort. Restorative procedures: enables painless cavity preparation, filling and crown placement during routine dentistry. Periodontal surgery: delivers effective numbness for gum grafts, flap procedures and scaling. Pediatric dental treatment: offers safe, controlled anesthesia for children undergoing various oral interventions. Orthodontic adjustments: reduces discomfort during bracket placement, wire changes and other corrective procedures.

Adverse reactions to Orabloc are generally related to the anesthetic agent or the vasoconstrictor component.

Common Side Effects: - Transient numbness: temporary loss of sensation in the injected area. - Tingling or metallic taste: brief sensory disturbances after injection. - Mild swelling or bruising: localized tissue reaction at the site. - Headache: occasional mild headache following the procedure.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or anaphylaxis requiring immediate care. - Cardiovascular events: hypertension, tachycardia, or arrhythmias due to epinephrine. - Central nervous system toxicity: seizures, dizziness, or prolonged numbness indicating possible overdose.

Prior to using Orabloc, clinicians should evaluate patient history and follow specific safety measures.

Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics or epinephrine. Cardiovascular status: assess hypertension, arrhythmias or other heart conditions before administration. Pregnancy consideration: use only when benefit outweighs potential risk, as data are limited. Drug interaction review: avoid concurrent MAO inhibitors and monitor use of β‑blockers or tricyclic antidepressants. Dosage limit: do not exceed the recommended maximum dose for the patient’s weight and procedure. Store at below 25°C: keep in original container, protect from light and moisture.

Articaine combined with epinephrine may interact with several medications, altering cardiovascular response or toxicity risk.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: can precipitate hypertensive crisis with epinephrine. - β‑blockers: may mask tachycardia and exacerbate hypertension. - Tricyclic antidepressants: increase risk of arrhythmias when combined with epinephrine. - Clonidine: may potentiate vasoconstrictive effects leading to severe hypertension. - Additional local anesthetics: cumulative toxicity risk if total dose exceeds safe limits.

Moderate Interactions (Monitor Closely): - Sympathomimetic agents (e.g., phenylephrine): may enhance cardiovascular stimulation. - Diuretics: can affect plasma volume and modify epinephrine’s hemodynamic impact. - ACE inhibitors or other antihypertensives: monitor blood pressure during and after injection.